论文部分内容阅读
目的:探讨重症肌无力患者采用免疫球蛋白治疗的最佳剂量。方法:选择2007年8月到2014年11月在我院收治的174例重症肌无力患者,随机分为ACS组、小剂量IgG组和大剂量IgG组,分别每日静脉滴注15 mg肾上腺素、250 mg免疫球蛋白和500 mg免疫球蛋白进行治疗,对比三组的临床疗效、住院时间和呼吸机辅助时间。结果:经过治疗后,小剂量IgG组与ACS组总有效率无显著性差异(P>0.05);大剂量IgG组总有效率明显高于小剂量IgG组和ACS组,具有显著性差异(P<0.05);大剂量IgG组患者的住院时间和呼吸机辅助时间均明显少于ACS组和小剂量IgG组,具有显著性差异(P<0.05)。结论:500 mg免疫球蛋白静脉滴注临治疗重症肌无力,临床疗效显著,能明显缩短患者的住院时间和呼吸机辅助时间,值得在临床上推广。
Objective: To investigate the best dose of immunoglobulin in patients with myasthenia gravis. Methods: A total of 174 patients with myasthenia gravis treated in our hospital from August 2007 to November 2014 were randomly divided into ACS group, low dose IgG group and high dose IgG group. Intravenous infusion of 15 mg epinephrine , 250 mg immunoglobulin and 500 mg immunoglobulin. The clinical efficacy, hospital stay and ventilator support time of the three groups were compared. Results: After treatment, there was no significant difference in total effective rate between low dose IgG group and ACS group (P> 0.05). The total effective rate of high dose IgG group was significantly higher than that of low dose IgG group and ACS group (P <0.05). The hospitalization time and ventilatory assist time of high-dose IgG group were significantly less than those of ACS group and low-dose IgG group (P <0.05). CONCLUSION: Intravenous infusion of 500 mg immunoglobulin for the treatment of myasthenia gravis has significant clinical effect, which can significantly shorten the hospitalization time and ventilator-assisted time, which is worth to be popularized clinically.